Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Bristol Myers Squibb
Biotech
Astellas ends $1.6B biobucks TCE pact with CytomX after 6 years
Astellas is ending its six-year, $1.6 billion biobuck partnership with CytomX Therapeutics aimed at exploring TCE bispecifics.
Will Maddox
Mar 16, 2026 10:12am
BMS' CELMoD drug improves myeloma PFS in phase 3
Mar 9, 2026 11:08am
BMS' ADC hits primary endpoints in phase 3 breast cancer trial
Feb 26, 2026 9:08am
Evinova reels in AI partnerships with Astellas and AZ deals
Feb 24, 2026 12:00pm
Angelini nocks an AI arrow with $120M Quiver deal
Feb 23, 2026 11:04am
How Biohaven is keeping its 'feet to the fire'
Feb 20, 2026 10:30am
